Navigation Links
Cardiotrophin 1 shows promising results for treatment of obesity and metabolic syndrome
Date:9/12/2011

Scientists from the Center for Applied Medical Research (CIMA) of the University of Navarra (Spain) have discovered that cardiotrophin 1, a protein synthesized by muscle cells and adipose tissue, has a marked effect on fat and glucose metabolism. "These new findings add to those we already know on this compound such the anti-ischemic and cytoprotective effects showed in acute liver damage and solid organ transplants gives CT-1 great possibilities to be developed in various serious conditions", commented Pablo Ortiz, CEO of Digna Biotech.

The study was published in the August issue of Cell Metabolism, most prestigious journal in Metabolism and further details were described in the 25th August of SciBX, the Biocentury/Nature publication. The researchers found that the administration of cardiotrophin 1 accelerates the elimination of fat from the adipose tissue and increases the rate at which fat is burnt in muscles. Treatment of obese and diabetic mice with cardiotrophin 1 increases energy expenditure, reduces food intake and corrects obesity and diabetes. Investigators noticed that, in addition to its effects on fat metabolism, cardiotrophin 1 promotes the entrance of glucose into the cells and increases the sensitivity to insulin. The investigation has been led by M. Bustos, J. Prieto and MJ Moreno-Aliaga at CIMA.

Cardiotrophin 1 is co-developed for its use in organ transplantation and tissue regeneration by Digna Biotech and Biotecnol (The Consortium). Both of the companies signed an Exclusive License and Option Agreement with Genentech, Inc (a fully owned subsidiary of the Roche group) on September 2009. Pablo Ortiz remarked: "Cardiotrophin 1 showed a very interesting effect on fat metabolism which deserves to be explored in a clinical setting. We are ready to recruit healthy volunteers in the Phase I trial before the end of the year. Phase II in liver resection is scheduled for the second quarter of 2012. We are also confident that these new applications and the progress on the clinical development will allow us to forge partnerships with other biopharmaceutical companies to reach the patients as soon as possible". According to Pedro de Noronha Pissarra, CEO of Biotecnol: "expanding the use of such a promising molecule to other fields of use, where unmet needs exist, will build additional value to the current work. Its clear from the current findings on the mechanism of action of Cardiotrophin 1 in fat metabolism, that clinical work should be pursued and potentially new partnerships in order to expand such work can now be equated".

Pre-clinicial and clinical development of cardiotrophin 1 was funded by private and public Spanish entities: ClaveSuan, the Center for Industrial and Technological Development (CDTI), and the Government of Navarra. Only in liver resection and transplantation, cardiotrophin 1 may generate revenues of 350 millions of euros per year.


'/>"/>

Contact: Nuria Safont
nsafont@dignabiotech.com
Digna Biotech S.L
Source:Eurekalert

Related biology news :

1. Long-term study shows effect of climate change on animal diversity
2. New approach to treating cystic fibrosis lung infection shows promise
3. Research shows Brazilian acai berry antioxidants absorbed by human body
4. Wildfires cause ozone pollution to violate health standards, new study shows
5. New CU-Boulder study shows diversity decreases chances of parasitic disease
6. U of MN study shows link between gene variations and cancer survival
7. New study shows drinking your vegetables may be a solution to bridging the vegetable gap
8. Mounting evidence shows health benefits of grape polyphenols
9. Research shows that the pill does not deserve its reputation for causing weight gain
10. New journal shows half-broken gene is enough to cause cancer
11. Research shows that time invested in practicing pays off for young musicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/26/2017)... 26, 2017  Acuity Market Intelligence today released ... Digital Identity".  Acuity characterizes 2017 as a "breakout" ... adoption reflects a new understanding of the potential ... and digital identity are often perceived as threats ... , Principal of Acuity Market intelligence. "However, taken ...
(Date:1/24/2017)... 2017  It sounds simple and harmless—an electronic ... vital signs and alerts parents on their smart ... level drops. But pediatric experts argue that such ... no evidence of medical benefits, especially to healthy ... to parents of healthy babies, promising peace of ...
(Date:1/19/2017)... India , January 19, 2017 According to a ... Opportunities and Forecast, 2014 - 2022," the global biometric sensor market is expected ... 2016 to 2022. In 2015, Asia-Pacific dominated the global ... and private sectors. Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or ... China, today announced its financial results for the fourth quarter ... 2016 Financial Highlights Total sales in ... terms, or increased by 13.6% in USD terms to $77.6 ... Gross profit increased by 13.3% to $46.8 ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... Discovery Services portfolio to include an array of biochemical analyses critical for ... data to drive their hit-to-lead and SAR programs, including inhibitor potency and selectivity, ...
(Date:2/23/2017)... 2017  Imanis Life Sciences announced today the ... vaccinia viruses for virotherapy research. These viruses are ... proprietary, vaccinia virus-based technology platform for research use. ... a partnership with Genelux to offer researchers, for ... use in research," said Dr. Kah Whye ...
(Date:2/23/2017)... ... , ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, NC ... GGI's mission is to advance global health and highlight the greater good of clinical ... each clinical trial volunteer. The vision of GGI is to serve as a philanthropic ...
Breaking Biology Technology: